CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Nafamostat MesilateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug184 ChAdOx1 MERS Wiki 0.71
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.15
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)

RACONA is a prospective trial that will test the hypothesis that nafamostat can lower lung function deterioration and need for intensive care admission in COVID-19 patients. Design: Adult hospitalized COVID-19 patients will be randomized in a prospective double-blind randomized placebo-controlled study to test the clinical efficacy of nafamostat mesylate (administered intravenously) on top of best standard of care. Primary outcome measures: the time-to-clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven category ordinal scale or live discharge from the hospital, whichever comes first.

NCT04352400 COVID19 Drug: Nafamostat Mesilate Drug: Placebo

Primary Outcomes

Description: Time-to-clinical improvement (time from randomization to an improvement of two points (from the status at randomization) on a 7 category ordinal scale or live discharge from the hospital, whichever came first.

Measure: Time-to-clinical improvement

Time: day 1 until day 28

Secondary Outcomes

Description: Rate of patients showing improvement of 2 points in 7 category ordinal scale (with 7 points the worst)(PubMed ID: 32187464)

Measure: Responders

Time: day 1 until day 28

Description: Proportion of patients who will progress to critical illness/death

Measure: Critical or dead patients

Time: day 1 until day 28

Description: Change in pO2/FiO2 ratio over time

Measure: pO2/FiO2 ratio

Time: day 1 until day 28

Description: Change Sequential organ failure assessment score (SOFA score) over time. The Score ranges from 0 to 24 (with 24 the worst)(PubMed ID: 11594901)

Measure: SOFA score over time

Time: day 1 until day 28

Description: Duration of hospitalization in survivors (days)

Measure: Hospitalization

Time: day 1 until day 28

Description: Number of patients who require ventilation

Measure: Mechanical ventilation

Time: day 1 until day 28

Description: Duration of ventilation (days)

Measure: Mechanical ventilation duration

Time: day 1 until day 28

Description: Proportion of patients who develop arrhythmia, or myocardial infarction, or other cardiovascular disease not present at the baseline

Measure: Cardiovascular disease

Time: day 1 until day 28


No related HPO nodes (Using clinical trials)